beta-Glucogallin

CAS No. 13405-60-2

beta-Glucogallin( —— )

Catalog No. M33086 CAS No. 13405-60-2

beta-Glucogallin (beta-Glucogallin) is a selective aldose reductase (AKR1B1) inhibitor with antioxidant, anti-glycation, and anti-inflammatory properties.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 85 In Stock
5MG 121 In Stock
10MG 176 In Stock
25MG 389 In Stock
50MG 674 In Stock
100MG 1233 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    beta-Glucogallin
  • Note
    Research use only, not for human use.
  • Brief Description
    beta-Glucogallin (beta-Glucogallin) is a selective aldose reductase (AKR1B1) inhibitor with antioxidant, anti-glycation, and anti-inflammatory properties.
  • Description
    β-Glucogallin is a potent and selective aldose reductase (AKR1B1) inhibitor. β-Glucogallin can be isolated from the medicinal plant Emblica officinalis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    Reductase
  • Recptor
    Reductase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    13405-60-2
  • Formula Weight
    332.26
  • Molecular Formula
    C13H16O10
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O(C(=O)C1=CC(O)=C(O)C(O)=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Li L, et al. Design of an amide N-glycoside derivative of β-glucogallin: a stable, potent, and specific inhibitor of aldose reductase. J Med Chem. 2014 Jan 9;57(1):71-7.?
molnova catalog
related products
  • Sulindac sulfone

    Sulindac sulfone is a metabolite of the nonsteroidal anti-inflammatory drug sulindac. Sulindac sulfone is an inhibitor of aldose reductase (IC50 =367 nM).

  • VU 0364770

    VU 0364770(EC50=1.1 μM), a positive allosteric modulator(PAM) of mGlu4, shows insignificant activity at 68 other receptors, including other mGlu subtypes.

  • WJ-39

    WJ-39 is an orally active aldose reductase (AR) inhibitor that ameliorates renal lesions in diabetic nephropathy through activation of Nrf2 signaling, and may be used to ameliorate renal insufficiency and fibrosis.